Nanotech Safety, Efficacy Models Exist, But Nomenclature Problematic – FDA
This article was originally published in The Gray Sheet
Executive SummaryFDA expects nanotechnology will be subject to the same efficacy standards demanded of medical devices, according to CDRH Office of Science & Engineering Laboratories Director Larry Kessler
You may also be interested in...
The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.